Thanks to the research of the European Pharmaceutical Review, we are witnessing a wide examination of how the pharmaceutical supply chain is faring in the face of growing concerns about the impact of a sudden market disruption on the quality and availability of medicines. A new report by the European Medicines and Healthcare Products Regulator (EMR) also shows that the necessary visibility is lacking to respond effectively to sudden market disruptions. The study authors identified the most cited challenges for supply chain executives. Despite these ongoing problems, many supply chains and companies recognize the value of supply chain visibility and are making efforts to improve it.
A program has been already created to expand access to high-quality, low-cost, high-quality drugs, increase competition in the marketplace, create stable pharmaceutical supply chains, alleviate drug scarcity, and mitigate irrational pricing for its member institutions. This has been achieved by a consortium focused on the pharmaceutical supply chain, whose members include manufacturers, CMOs, wholesalers, and dispensers, including pharmaceutical companies, drug distributors, pharmacies, medical device manufacturers, and medical device manufacturers. This will allow supply chain organizations to gather more information about the risks and opportunities of their supply chains. Identifying and preventing these risks and preventing them can lead to process efficiency and reduced productivity due to business risks. Pharmaceutical companies will not only help health systems meet their health needs but will also prevent the costs and costs of their own and their patients in the health care system.
No one from the industry players is opposed to measures that help ensure the integrity of the pharmaceutical supply chain. Improved visibility is already having a positive impact on the quality and security of supply chains and the health system, but we need a security boost in supply chains to enable the integration of information flow across supply chains. The industry leaders advise monitoring geographical and geopolitical developments to prevent potential supply chain disruptions and to act appropriately with resources. Of course, the constant monitoring and control of supply chains in the pharmaceutical business are crucial. Moreover, visibility could be achieved by making the supply chain more visible, which has been easier for manufacturers in recent years.
Moreover, a key to maintaining the quality of the supply chain, and the availability of more breakthrough medicines that can bring them to the global market more quickly must be identified. In an article, PharmaNewsIntelligence breaks down the fundamentals of pharmaceutical supply chains and reveals the most common challenges to be addressed and ways to provide patients with uniform access to their medicines.
The purpose of the paper was to investigate the impact of supply chain integration on the quality of pharmaceutical supply chains in the United States. The study sought to examine the factors responsible for the poor visibility of drugs on the US market and to find the variables that influence this problem. Value creation through supply chain integration: review and analysis of data from the US Food and Drug Administration (FDA).
Apart from the launch of a supply chain map that allows consumers to see all the supply chains associated with a product, pharmaceutical manufacturers are struggling with a particularly complex supply chain. Pharmaceutical supply chains – Supply chains include pharmaceuticals, medical devices, pharmaceutical products, and other pharmaceutical products. Supply chain barriers are prevalent throughout the industrial sector but are not always visible to consumers.
Such a lack of accountability increases the risk of corruption in procurement and distribution. Further supply chain complications arise from mergers and acquisitions, which are likely to cause quality control problems, albeit temporarily. Trying to integrate new products such as new medicines, new manufacturing processes, and new technologies can lead to bottlenecks and customer dissatisfaction. This often leads to problems in tracking supply flows across supply chains, as well as poor quality assurance and quality management. Although some of this internals may be possible, many pharmaceutical companies are still falling by the wayside due to a lack of transparency in the supply chain.
Supply chain leaders need to develop the supply-chain mental model to include more than just the physical location of their supply lines. To achieve a better understanding of supply chain management strategy and its identification, it is essential to develop a supply chain management strategy that includes the mapping of supply networks. As mentioned above, it has become necessary to make several resources and progress in terms of delivery times visible.